Fundraising FoxOmega Funds — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalLongitude CapitalCatalio Capital Management, LPOrbiMedAvoro Capital AdvisorsDigitalis Ventures
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsBrandon CapitalCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankM Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ikena Oncology, Inc.Callio Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.